Supportive Care and Managing Toxicities Related to ADCs in TNBC

The FDA has approved pertuzumab-dpzb (Poherdy) as a biosimilar to pertuzumab (Perjeta) in breast cancer, based on a review of various attributes, including safety and efficacy data.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Dato-DXd is being assessed in numerous trials across the breast, lung, and bladder cancer spaces.

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Aditya Bardia, MD, highlights the successes and challenges associated with ADC treatments in breast cancer.

Explore the latest advancements in antibody-drug conjugates for treating metastatic triple-negative breast cancer, enhancing patient outcomes and safety.